Durvalumab vs Nivolumab

## Durvalumab vs Nivolumab: Overview

This comparison examines the pharmacological differences between **Durvalumab** and **Nivolumab**.

## Mechanism of Action

**Durvalumab**: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

**Nivolumab**: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.

## Pharmacokinetics

**Half-life**: Durvalumab — 17 days; Nivolumab — 27 days.

## Chemical Properties

**Type**: Durvalumab — Antibody; Nivolumab — Antibody.